Information Provided By:
Fly News Breaks for July 19, 2018
Jul 19, 2018 | 05:21 EDT
Piper Jaffray analyst Edward Tenthoff recommends using the 32% selloff this week in shares of Aveo Pharmaceuticals as a buying opportunity. He reiterates an Overweight rating on the name with a $5 price target. The analyst views the pullback on news of data from the Phase III Tivo-3 trial of tivozanib in third-line renal cell carcinoma coming in Q4 as an overreaction. Tenthoff continues to believe Tivo-3 will be positive based on prior Tivo-1 progression-free survival benefit versus historical sorafenib. With positive Tivo-3 data, Aveo could respond to the 2013 tivozanib complete response letter with potential FDA approval next year, Tenthoff tells investors in a research note.
News For AVEO From the Last 2 Days
There are no results for your query AVEO
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.